Currently, three main therapeutic strategies for sunitinib-resistant ccRCC are sunitinib com-bination therapy, sequential therapy with VEGFR inhibitors, and anti-cancer vaccines. The gene discussed is KDR; the disease is nonpapillary renal cell carcinoma.